94. 原発性硬化性胆管炎
[臨床試験数:134,薬物数:105(DrugBank:37),標的遺伝子数:18,標的パスウェイ数:131

Searched query = "Primary sclerosing cholangitis", "PSC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
10 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03035058
(ClinicalTrials.gov)
February 201725/1/2017Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel DiseaseA Randomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying Inflammatory Bowel DiseasePrimary Sclerosing Cholangitis;Inflammatory Bowel DiseaseDrug: Vedolizumab;Drug: PlaceboTakedaNULLWithdrawn18 YearsN/AAll0Phase 3NULL
2EUCTR2014-003942-28-PL
(EUCTR)
15/06/201631/05/2016Efficacy and Safety of Vedolizumab IV in the treatment of PrimarySclerosing Cholangitis in patients with Inflammatory Bowel DiseaseRandomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying Inflammatory Bowel Disease - Primary Sclerosing Cholangitis (PSC)Inflammatory Bowel Disease (IBD)
MedDRA version: 19.0;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871
MedDRA version: 19.0;Level: PT;Classification code 10021972;Term: Inflammatory bowel disease;System Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 19.0;Classification code 10021973;Term: Inflammatory bowel disease NOS;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Entyvio
Product Name: Vedolizumab IV
Product Code: MLN0002
INN or Proposed INN: Vedolizumab
Other descriptive name: VEDOLIZUMAB
Takeda Development Centre Europe, Ltd.NULLNot RecruitingFemale: yes
Male: yes
258Phase 3United States;Finland;Spain;Austria;Russian Federation;Israel;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Denmark;Bulgaria;Netherlands;Germany;Japan;Sweden
3EUCTR2014-003942-28-ES
(EUCTR)
29/05/201624/02/2016Efficacy and Safety of Vedolizumab IV in the treatment of PrimarySclerosing Cholangitis in patients with Inflammatory Bowel DiseaseRandomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying Inflammatory Bowel Disease Primary Sclerosing Cholangitis (PSC)Inflammatory Bowel Disease (IBD)
MedDRA version: 19.0;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871
MedDRA version: 19.0;Level: PT;Classification code 10021972;Term: Inflammatory bowel disease;System Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 19.0;Classification code 10021973;Term: Inflammatory bowel disease NOS;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Entyvio
Product Name: Vedolizumab IV
Product Code: MLN0002
INN or Proposed INN: Vedolizumab
Other descriptive name: VEDOLIZUMAB
Takeda Development Centre Europe, Ltd.NULLNot RecruitingFemale: yes
Male: yes
258Phase 3United States;Finland;Spain;Austria;Russian Federation;Israel;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Denmark;Bulgaria;Netherlands;Germany;Japan;Sweden
4EUCTR2014-003942-28-GB
(EUCTR)
26/05/201618/03/2016Efficacy and Safety of Vedolizumab IV in the treatment of PrimarySclerosing Cholangitis in patients with Inflammatory Bowel DiseaseRandomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying Inflammatory Bowel Disease Primary Sclerosing Cholangitis (PSC)Inflammatory Bowel Disease (IBD)
MedDRA version: 18.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871
MedDRA version: 18.1;Level: PT;Classification code 10021972;Term: Inflammatory bowel disease;System Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 18.1;Classification code 10021973;Term: Inflammatory bowel disease NOS;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Entyvio
Product Name: Vedolizumab IV
Product Code: MLN0002
INN or Proposed INN: Vedolizumab
Other descriptive name: VEDOLIZUMAB
Takeda Development Centre Europe, Ltd.NULLNot RecruitingFemale: yes
Male: yes
258Phase 3United States;Finland;Spain;Austria;Russian Federation;Israel;Switzerland;United Kingdom;Italy;France;Czech Republic;Hungary;Canada;Poland;Belgium;Denmark;Bulgaria;Netherlands;Germany;Japan;Sweden
5EUCTR2014-003942-28-BE
(EUCTR)
13/05/201610/03/2016Efficacy and Safety of Vedolizumab IV in the treatment of PrimarySclerosing Cholangitis in patients with Inflammatory Bowel DiseaseRandomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying Inflammatory Bowel Disease Primary Sclerosing Cholangitis (PSC)Inflammatory Bowel Disease (IBD)
MedDRA version: 18.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871
MedDRA version: 18.1;Level: PT;Classification code 10021972;Term: Inflammatory bowel disease;System Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 18.1;Classification code 10021973;Term: Inflammatory bowel disease NOS;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Entyvio
Product Name: Vedolizumab IV
Product Code: MLN0002
INN or Proposed INN: Vedolizumab
Other descriptive name: VEDOLIZUMAB
Takeda Development Centre Europe, Ltd.NULLNot RecruitingFemale: yes
Male: yes
258Phase 3United States;Finland;Spain;Austria;Russian Federation;Israel;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Denmark;Bulgaria;Netherlands;Germany;Japan;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2014-003942-28-DE
(EUCTR)
09/05/201623/03/2016Efficacy and Safety of Vedolizumab IV in the treatment of PrimarySclerosing Cholangitis in patients with Inflammatory Bowel DiseaseRandomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying Inflammatory Bowel Disease Primary Sclerosing Cholangitis (PSC)Inflammatory Bowel Disease (IBD)
MedDRA version: 18.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871
MedDRA version: 18.1;Level: PT;Classification code 10021972;Term: Inflammatory bowel disease;System Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 18.1;Classification code 10021973;Term: Inflammatory bowel disease NOS;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Entyvio
Product Name: Vedolizumab IV
Product Code: MLN0002
INN or Proposed INN: Vedolizumab
Other descriptive name: VEDOLIZUMAB
Takeda Development Centre Europe, Ltd.NULLNot RecruitingFemale: yes
Male: yes
258Phase 3United States;Finland;Spain;Austria;Russian Federation;Israel;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Denmark;Bulgaria;Netherlands;Germany;Japan;Sweden
7EUCTR2014-003942-28-HU
(EUCTR)
09/05/201621/03/2016Efficacy and Safety of Vedolizumab IV in the treatment of PrimarySclerosing Cholangitis in patients with Inflammatory Bowel DiseaseRandomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying Inflammatory Bowel Disease Primary Sclerosing Cholangitis (PSC)Inflammatory Bowel Disease (IBD)
MedDRA version: 18.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871
MedDRA version: 18.1;Level: PT;Classification code 10021972;Term: Inflammatory bowel disease;System Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 18.1;Classification code 10021973;Term: Inflammatory bowel disease NOS;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Entyvio
Product Name: Vedolizumab IV
Product Code: MLN0002
INN or Proposed INN: Vedolizumab
Other descriptive name: VEDOLIZUMAB
Takeda Development Centre Europe, Ltd.NULLNot RecruitingFemale: yes
Male: yes
258Phase 3United States;Finland;Spain;Austria;Russian Federation;Israel;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Denmark;Bulgaria;Netherlands;Germany;Japan;Sweden
8EUCTR2014-003942-28-AT
(EUCTR)
13/04/201624/03/2016Efficacy and Safety of Vedolizumab IV in the treatment of PrimarySclerosing Cholangitis in patients with Inflammatory Bowel DiseaseRandomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying Inflammatory Bowel Disease Primary Sclerosing Cholangitis (PSC)Inflammatory Bowel Disease (IBD)
MedDRA version: 18.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871
MedDRA version: 18.1;Level: PT;Classification code 10021972;Term: Inflammatory bowel disease;System Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 18.1;Classification code 10021973;Term: Inflammatory bowel disease NOS;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Entyvio
Product Name: Vedolizumab IV
Product Code: MLN0002
INN or Proposed INN: Vedolizumab
Other descriptive name: VEDOLIZUMAB
Takeda Development Centre Europe, Ltd.NULLNot RecruitingFemale: yes
Male: yes
258Phase 3United States;Finland;Spain;Austria;Russian Federation;Israel;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Denmark;Bulgaria;Netherlands;Germany;Japan;Sweden
9EUCTR2014-003942-28-CZ
(EUCTR)
12/04/201624/03/2016Efficacy and Safety of Vedolizumab IV in the treatment of PrimarySclerosing Cholangitis in patients with Inflammatory Bowel DiseaseRandomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying Inflammatory Bowel Disease Primary Sclerosing Cholangitis (PSC)Inflammatory Bowel Disease (IBD)
MedDRA version: 19.0;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871
MedDRA version: 19.0;Level: PT;Classification code 10021972;Term: Inflammatory bowel disease;System Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 19.0;Classification code 10021973;Term: Inflammatory bowel disease NOS;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Entyvio
Product Name: Vedolizumab IV
Product Code: MLN0002
INN or Proposed INN: Vedolizumab
Other descriptive name: VEDOLIZUMAB
Takeda Development Centre Europe, Ltd.NULLNot RecruitingFemale: yes
Male: yes
258Phase 3United States;Finland;Spain;Austria;Russian Federation;Israel;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Denmark;Bulgaria;Netherlands;Germany;Japan;Sweden
10EUCTR2014-003942-28-SE
(EUCTR)
30/03/201621/03/2016Efficacy and Safety of Vedolizumab IV in the treatment of PrimarySclerosing Cholangitis in patients with Inflammatory Bowel DiseaseRandomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying Inflammatory Bowel Disease Primary Sclerosing Cholangitis (PSC)Inflammatory Bowel Disease (IBD)
MedDRA version: 18.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871
MedDRA version: 18.1;Level: PT;Classification code 10021972;Term: Inflammatory bowel disease;System Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 18.1;Classification code 10021973;Term: Inflammatory bowel disease NOS;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Entyvio
Product Name: Vedolizumab IV
Product Code: MLN0002
INN or Proposed INN: Vedolizumab
Other descriptive name: VEDOLIZUMAB
Takeda Development Centre Europe, Ltd.NULLNot RecruitingFemale: yes
Male: yes
258Phase 3United States;Finland;Spain;Austria;Russian Federation;Israel;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Denmark;Bulgaria;Netherlands;Germany;Japan;Sweden